Global Sjögren's Syndrome treatment market to double to $2.2 bn by 2024

Driven primarily by the launch of Bristol-Myers Squibb's Orencia from 2021

twitter-follower-growth

(Photo Courtesy: www.adweek.com)

The Sjögren's syndrome treatment market will experience impressive growth over the next decade, doubling from $1.1 billion in 2014 to $2.2 billion by 2024, driven primarily by the launch of Bristol-Myers Squibb's Orencia from 2021, according to research and consulting firm GlobalData.

The company's latest report states that this increase, which is forecast across the seven Major Markets (7MM) of the US, Japan, the UK, France, Spain, Italy and Germany, represents a considerable Compound Annual Growth Rate (CAGR) of 7.2%.

Dr Haylyn Wong, GlobalData's Senior Analyst covering Cardiovascular and Metabolic Disorders, says that Orencia (abatacept), the first biologic agent for the treatment of Sjögren's syndrome, is anticipated to launch across the 7MM by 2022.

Dr Wong explains: "Orencia is currently in Phase III of development, and has so far demonstrated positive results in treating Sjögren's syndrome. A small open-label pilot study has shown that the drug significantly reduces disease activity, with most improvement seen in pain and fatigue scores.

"GlobalData believes that Orencia will capture patient share from existing Sjögren's syndrome patients receiving systemic immunosuppressants and corticosteroids, and to a smaller degree from patients receiving antimalarial agents who are not adequately managed."

 

Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

GST

GST: Boon or Bane for Healthcare?

Send this article by email

X